Biodesix And Inivata To Investigate Clinical Utility Of Next Generation Sequencing-Blood Based Tests For Patients With Advanced Lung Cancer
Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.